Table 2.
Ex vivo measures of 18F-FDG in IBAT and WAT
| Groups | IBAT | WAT | Ratio (IBAT/WAT) | |||
|---|---|---|---|---|---|---|
|
Autorad
a
(10 6 DLU/mm 2 ) |
Autopsy
b
(kBq/g/(MBq/kg)) |
Autorad
a
(10 6 DLU/mm 2 ) |
Autopsy
b
(kBq/g/(MBq/kg)) |
Autorad
a
(10 6 DLU/mm 2 ) |
Autopsy
b
(kBq/g/(MBq/kg)) |
|
| Control | 1.6 ± 0.2** | 4.3 ± 0.4** | 0.5 ± 0.1 | 1.6 ± 0.1 | 3.2 ± 0.2 | 2.7 ± 0.1 |
| CL316,243-treated | 13.7 ± 0.1*, ** | 68.1 ± 18.0*, ** | 1.1 ± 0.3* | 2.4 ± 0.2* | 12.5 ± 3.3* | 27.6 ± 5.5* |
aResults of autoradiography in transverse sections of IBAT and the surrounding WAT mean ± SD, n = 3; *p < 0.05 as compared to the control; **p < 0.05 as compared to WAT; bResults of counted radioactivity concentrations in autopsied IBAT and the surrounding WAT mean ± SD, n = 3; *p < 0.05 as compared to the control; **p < 0.05 as compared to WAT. IBAT, interscapular brown adipose tissue; WAT, white adipose tissue; CL316,243, (R, R)-5-[2-[2,3-(3-chlorphenyl)-2-hydroxyethyl-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate, disodium salt.